Drug Patients (n ... In the treatment of rheumatoid arthritis, switching among biologic agents has become established practice when patients fail to achieve a response, lose response or experience ...

Rheumatoid arthritis (RA) can be a challenging and painful condition to manage. Biologics are one type of disease-modifying antirheumatic drugs (DMARDs) your doctor might prescribe to treat RA.

Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA ... concomitant medications and illnesses, dates of studies performed ...

There is a bidirectional association between rheumatoid arthritis (RA ... Analgesia (painkillers) and anti-inflammatory drugs, including steroids, are used to suppress the symptoms, while disease ...

Differences in rates of bDMARD treatment initiation among US veterans with RA living in rural vs urban areas cannot be fully explained by location.

University of Birmingham researchers have been awarded £3.5 million funding from Johnson & Johnson to investigate mechanisms of response and non-response to biologic and targeted synthetic therapies ...

Chronic joint pain is a problem that affects millions of people worldwide. It can make everyday activities like walking, ...

Early treatment escalation to biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) following methotrexate (MTX) failure in new-onset rheumatoid arthritis (RA) does not ...

Postmenopausal women, particularly those who experience early menopause, may have a higher risk for developing rheumatoid arthritis (RA ... The use of biologic and targeted therapies for children ...

Germany's biologics market, the largest in Europe, is expected to grow at a 3.8% CAGR from 2025 to 2035. AI is driving this growth by enhancing R&D, optimizing drug design, and identifying novel ...